# HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

> **NCT03569891** · PHASE3 · COMPLETED · sponsor: **CSL Behring** · enrollment: 67 (actual)

## Conditions studied

- Hemophilia B

## Interventions

- **GENETIC:** AAV5-hFIXco-Padua
- **BIOLOGICAL:** Factor IX (FIX)

## Key facts

- **NCT ID:** NCT03569891
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-27
- **Primary completion:** 2021-09-22
- **Final completion:** 2025-03-19
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03569891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03569891, "HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03569891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*